Articles

E-mail RSS

Cambridge, MA - Genstruct Inc., a knowledge-driven discovery company using systems biology to increase the effectiveness of drug discovery and development, recently announced that it has achieved its first performance milestone in its multi-year relationship with Pfizer to help understand and treat complex diseases. The objective of this partnership is to discover critical scientific insights from large systems biology datasets in real time, and to provide causal models to answer complex therapeutic questions.

"The completion of this milestone is an important achievement in our collaboration with Pfizer," said Keith O. Elliston, Ph.D., president and CEO of Genstruct. "We have used our proprietary technology and methodology to help Pfizer's Worldwide Safety Sciences Group investigate mechanisms of toxicity and develop biomarkers for compounds in development. We look forward to continued success in our relationship with Pfizer."

The first milestone included the development of causal system models that have been used to identify molecular mechanisms and biomarkers, and concluded with the delivery of a detailed scientific report to Pfizer that elucidates the potential mechanisms of toxicity that led to the identification of rational mechanism-based biomarkers.

The multi-year agreement is the third agreement between Genstruct and Pfizer and was signed in late 2004. The details of the financial terms were not disclosed. This deal also includes research projects with Pfizer's Discovery and Clinical Sciences units.

SOURCE: Genstruct